Synopsis: The US FDA has placed Dabur India’s Silvassa manufacturing facility under Import Alert 66-40 following an inspection that found falsified manufacturing records and grossly unsanitary conditions; with the affected revenue below 1 percent of consolidated sales, the immediate financial damage is contained, but the record falsification finding raises governance concerns that could meaningfully complicate and extend the remediation timeline.
Shares of one of India’s largest FMCG and Ayurvedic companies came under pressure after the US Food and Drug Administration issued a formal import alert against one of its manufacturing plants. The regulatory action, dated June 10, 2026, placed the Dadra and Nagar Haveli facility under Import Alert 66-40, authorising US customs authorities to detain outbound shipments from the unit without physical inspection of individual batches.
With a market capitalization of Rs. 75,171.23 crore, the shares of Dabur were trading at Rs. 423.75 per share, down 0.49 percent from its previous close of Rs.421.70. It is trading at a P/E of 39.99.
Regulatory Update
Import Alert 66-40 operates through a mechanism called Detention Without Physical Examination. Once invoked, US port authorities can automatically detain every incoming consignment from the flagged facility without testing individual batches for compliance. The bar to lifting such an alert is intentionally high: the facility must demonstrate to the US FDA that its corrective and preventive action plan has been fully implemented and independently verified, a process that routinely runs for several months and, in serious cases, extends beyond a year.
The US FDA’s inspection of the Silvassa plant produced an Establishment Inspection Report citing two categories of failure: data integrity and facility maintenance. Dabur submitted a corrective response after receiving the EIR, but the regulator determined it was insufficient to avoid enforcement action, triggering the alert.
What the Inspection Found
Independent investigative reports have surfaced with more specific details about the findings. Inspectors discovered that manufacturing records had been actively falsified to conceal the cross-use of specialised equipment across product lines equipment meant for exclusive use on certain formulations and requiring documented clearance before repurposing. This is not a paperwork lapse. Falsifying records to obscure undocumented cross-contamination risk is the class of finding that invites escalated regulatory action, not just remediation.
On the contamination front, inspectors found a live bird and bird droppings inside the raw material warehouse, approximately 30 feet from exposed packaging materials. Basic cleaning and equipment sanitation protocols across the over-the-counter manufacturing lines were similarly found deficient.
Financial Impact and Management Response
Dabur has moved quickly to limit investor anxiety by drawing a tight perimeter around the affected operations. The import alert targets a discrete section of the Silvassa plant dedicated entirely to private-label products exported to North America, a segment contributing less than 1 percent of consolidated group revenue. The company has stated that internal and independent third-party testing confirmed none of its products are out-of-specification or contaminated, and that domestic supply chains are fully unaffected.
The Silvassa plant continues operating for the Indian market under FSSAI jurisdiction, which sits outside the US FDA’s authority. To protect its North American private-label contracts in the interim, Dabur is redirecting manufacturing to other facilities within its global production network.
The counterpoint to that reassurance is the nature of the deficiency itself. Record falsification findings are treated categorically differently from environmental or maintenance lapses by US regulators; they imply deliberate concealment rather than operational negligence, and they tend to lengthen the scrutiny period. Historically, Import Alert 66-40 has served as a precursor to a formal Warning Letter; if one is issued, Dabur would face a more intensive bilateral remediation process before the alert is lifted.
Business Overview
Dabur India Limited is the world’s largest Ayurvedic and natural healthcare company and one of the top four Fast-Moving Consumer Goods (FMCG) players in India. Founded in 1884 by Dr. S.K. Burman, the company has evolved from a small proprietary medicine clinic in Kolkata into a global consumer goods major. According to Dabur’s Financial Statements, the company recorded an annual consolidated revenue from operations of Rs.12,563 crore.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
